Kala Bio Inc
KALA
Company Profile
Business description
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Contact
1167 Massachusetts Avenue
ArlingtonMA02476
USAT: +1 781 996-5252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,738.30 | 118.30 | -1.34% |
| CAC 40 | 8,119.02 | 51.07 | -0.63% |
| DAX 40 | 23,590.52 | 286.03 | -1.20% |
| Dow JONES (US) | 46,590.24 | 557.24 | -1.18% |
| FTSE 100 | 9,675.43 | 22.94 | -0.24% |
| HKSE | 25,953.30 | 430.98 | -1.63% |
| NASDAQ | 22,708.07 | 192.52 | -0.84% |
| Nikkei 225 | 48,938.91 | 1,385.00 | -2.75% |
| NZX 50 Index | 13,342.82 | 156.22 | -1.16% |
| S&P 500 | 6,672.41 | 61.70 | -0.92% |
| S&P/ASX 200 | 8,469.10 | 109.70 | -1.28% |
| SSE Composite Index | 3,940.93 | 31.11 | -0.78% |